FindMyKOL
Clinical trialNCT04219904Active, not recruitingPhase Early 1Interventional

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

NCT04219904 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Gadobutrol in Stage IA Cervical Cancer, Stage IA1 Cervical Cancer and 5 more conditions. The registry lists an enrollment of 25 participants at 1 site in 1 country. The registry lists a start date of 7 Sept 2018 and a primary completion date of 30 Sept 2027.

SponsorM.D. Anderson Cancer CenterEnrollment25Stage IA Cervical CancerStage IA1 Cervical CancerStage IA2 Cervical CancerStage IB Cervical CancerStage IB1 Cervical CancerStage IB2 Cervical Cancer+1 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04219904
FieldValue
Registry IDNCT04219904
StatusActive not recruiting
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment25
Registered sites1
Countries1
ConditionsStage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer and 1 more condition
DrugsGadobutrol
Start7 Sept 2018
Primary completion30 Sept 2027
Study completion30 Sept 2027
Last update posted10 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial studies how well positron emission tomography/magnetic resonance imaging (PET/MRI) scan works in checking patients with stage IA1-IB3 cervical cancer that can be removed by surgery (resectable). PET/MRI scan may help doctors learn more about the spread of the disease.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • M D Anderson Cancer Center

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gadobutrol
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04219904

Each answer restates registry values shown on this page.

What is NCT04219904?

NCT04219904 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Gadobutrol in Stage IA Cervical Cancer, Stage IA1 Cervical Cancer and 5 more conditions.

Is NCT04219904 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04219904?

The registry names Sanaz Javadi (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT04219904 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04219904 study?

The registered drug and biological interventions are Gadobutrol.

When is NCT04219904 expected to complete?

The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 10 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.